Frost & Sullivan Orthopedic Biomaterials Analyst Briefing


Published on

Frost & Sullivan’s analyst briefing on the orthopedic biomaterials market.

Published in: Technology, Health & Medicine
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Frost & Sullivan Orthopedic Biomaterials Analyst Briefing

  1. 1. Orthopedic Biomaterials Realities of the Material World Aarti Shetty, Industry Analyst Medical Devices, Healthcare September 25, 2008
  2. 2. Focus Points • Introduction • Segmentation • Advances in Implant Materials • Advances in Bone Graft Materials • Challenges of the Material Market • Market Future 2
  3. 3. Introduction • While the orthopedic industry has enjoyed double-digit growth over the past few years, the future is expected to be even brighter. • With this anticipated growth in the orthopedic industry, the demand for raw materials will also increase. • Our focus today – Trends and Future of the Biomaterials Market 3
  4. 4. Segmentation Orthopedic Biomaterials Orthopedic Bone Implants Grafts 4
  5. 5. Biomaterials: Booming Business Opportunity • The global orthopedic biomaterials market, valued at $4 billion in 2006, is projected to more than double by 2012, to $8.8 billion • Ageing Population and Lifestyle Changes • Technology Innovation • Growth through Partnerships • Growing Acceptance of Bone Graft Products 5
  6. 6. Market Challenges • Limited Number of Suppliers • Demonstrating Product Efficacy and Cost Savings • Costs Involved in R&D 6
  7. 7. Orthopedic Implants
  8. 8. Metals • In the past few years, high demand for titanium by the aerospace industry has driven up the price by a magnitude of four. • It is estimated that titanium is costing companies approximately 10 times the cost of certain grades of stainless steels. • A variety of other metals can be used in orthopedic applications, including cobalt-chrome and newer materials such as Nitinol 8
  9. 9. Implantable Plastics • Biocompatibility and High Performance • Mechanical Properties/Processing Technologies • Non-metallic • UHMWPE, PEEK, Bioabsorbables • Adoption 9
  10. 10. Ceramics • Ceramic product sales, which made up 25% of the market in 2006, are projected to grow at a steady CAGR of 10% between now and 2012 • Widely used in Europe and Japan than in the United States • Higher cost • Bio-ceramic materials 10
  11. 11. Bone Grafts Market
  12. 12. Spinal Fusion Using Human Bone 100 80 60 40 20 0 2001 2002 2003 2004 2005 2006 2007 Lumbar Cervical % of Interbody Spinal Fusion made of human bone • Well-publicized events involving the safety and legality of donated tissue and the general hassles involved in obtaining human tissue • Trend toward increased usage of non-human devices in the spine 12
  13. 13. Bone Morphogenetic Protein (BMP) • These products are expected to grow at a CAGR of 25% to $2.9 billion by 2012, accounting for 39% of the ortho biomaterials Revenue ($ Million) market. 800 600 400 • The BMP market segment grew 200 9% YOY in 2007 in contrast to its 0 39% in 2006. 2005 2006 2007 Year • Two products commercially Source: Frost & Sullivan available in the U.S. in the BMP sector: Medtronic’s InFuse and Stryker’s OP-1. 13
  14. 14. Bone Graft Substitutes • New technologies will drive U.S. bone graft substitute market to reach almost $1.9 billion by 2012 • Advanced BGS technologies has increased competition within the field • With the acquisition of Osiris Therapeutics' Osteocel business, NuVasive has obtained the first off- the-shelf bone graft substitute (BGS) product to incorporate viable stem cells 14
  15. 15. Companies in Spotlight Intergra Lifesciences/Isotis ISTO Technologies Fziomed Pegasus ETEX 15
  16. 16. Recent Products • Pioneer Surgical Technology, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market FortrOss, a novel bone graft substitute utilizing the power of nanotechnology for orthopedic applications in September 2008. • ETEX Corporation launched an innovative orthobiologic in August 2008, EquivaBone(TM). EquivaBone(TM) is a bone graft substitute that remodels and is replaced with new bone during the healing process. • Biocomposites received FDA 510(k) clearance for their unique bone graft substitute, geneX putty in July 2008. 16
  17. 17. Conclusion – Market Future • The biomaterials market is expected to be the next big factor in competitiveness for orthopedic implant manufacturers to differentiate themselves in the market. • As materials research continues, more options will become available for orthopedic manufacturers. These new materials will not only help improve products already on the market, but also will enable the creation of products previously thought impossible. 17
  18. 18. Your Feedback is Important to Us What would you like to see from Frost & Sullivan? Growth Forecasts? Competitive Structure? Emerging Trends? Strategic Recommendations? Other? Please inform us by taking our survey. 18
  19. 19. For Additional Information • To leave a comment, ask the analyst a question, or receive the free audio segment that accompanies this presentation, please contact Stephanie Ochoa, Social Media Manager at (210) 247- 2421, via email,, or on Twitter at 19